Subject : Plecanatide Clinician’s Perspective in the Management of Chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C)
Chronic constipation is among the most common gastrointestinal disorders. The prevalence of constipation-related issues tends to increase with age and is approximately two-fold greater in females than males. In particular, the prevalence of constipation gradually increases after 50 year of age, with a marked increase after 70 years of age.
Chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) are two of the most common functional gastrointestinal disorders that likely represent a spectrum of disease. CIC is characterized by difficult, infrequent, or incomplete bowel movements and can be accompanied by bloating and discomfort. IBS-C is characterized by abdominal pain and/or discomfort that is associated with defecation and hard or lumpy stool consistency. In the past, CIC and IBS-C were considered separate and distinct disorders; however, these disorders often coexist in patients and, because symptoms wax and wane over time, can be difficult to differentiate in routine clinical practice. Furthermore, Rome IV criteria support the emerging concept of CIC and IBS-C as a continuous spectrum of disorders with overlapping symptoms.
Prosecretory agents are efficacious in the treatment of CIC and IBS-C; however, data are limited regarding the safety and efficacy of these agents for the treatment of constipation in elderly populations. Plecanatide is a guanylate cyclase-C agonist that is approved for the treatment of adults with CIC and IBS-C. Approval was based on the results of four Phase III clinical trials, two in CIC and two in IBS-C. The studies represent the largest Phase III trials to date in each of these disorders, and they permitted enrollment of eligible patients up to the ages of 80 years (CIC) and 85 years (IBS-C).
Clinical perspective from Indian healthcare practitioners about Plecanatide can help other practicing HCPs in the management of CIC and IBS-C.
If you agree to participate, you will be required to respond to questions of the enclosed questionnaire. We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate to share your clinical perspective on Plecanatide. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})